<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Tenofovir disoproxil fumarate and emtricitabine: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Tenofovir disoproxil fumarate and emtricitabine: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Tenofovir disoproxil fumarate and emtricitabine: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="8527" href="/d/html/8527.html" rel="external">see "Tenofovir disoproxil fumarate and emtricitabine: Drug information"</a> and <a class="drug drug_patient" data-topicid="11362" href="/d/html/11362.html" rel="external">see "Tenofovir disoproxil fumarate and emtricitabine: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5708729"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Posttreatment acute exacerbation of hepatitis B:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Severe, acute exacerbations of hepatitis B virus (HBV) have been reported in HBV-infected individuals who have discontinued emtricitabine/tenofovir disoproxil fumarate. Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in individuals who are infected with HBV and discontinue emtricitabine/tenofovir disoproxil fumarate. If appropriate, initiation of antihepatitis B therapy may be warranted.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Risk of drug resistance with use for preexposure prophylaxis:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Emtricitabine/tenofovir disoproxil fumarate used for HIV-1 preexposure prophylaxis must only be prescribed to individuals confirmed to be HIV-negative immediately prior to initiating and at least every 3 months during use. Drug-resistant HIV-1 variants have been identified with use of emtricitabine/tenofovir disoproxil fumarate for HIV-1 preexposure prophylaxis following undetected acute HIV-1 infection. Do not initiate emtricitabine/tenofovir disoproxil fumarate for HIV-1 preexposure prophylaxis if signs or symptoms of acute HIV-1 infection are present unless negative infection status is confirmed.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F164681"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Truvada</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52912001"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>AG-Emtricitabine/Tenofovir;</li>
<li>APO-Emtricitabine-Tenofovir;</li>
<li>AURO-Emtricitabine-Tenofovir;</li>
<li>JAMP Emtricitabine/Tenofovir;</li>
<li>MINT-Emtricitabine/Tenofovir;</li>
<li>MYLAN-Emtricitabine/Tenofov DF;</li>
<li>PMS-Emtricitabine-Tenofovir;</li>
<li>TEVA-Emtricitabine/Tenofovir;</li>
<li>Truvada</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1010698"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antiretroviral Agent</span>;</li>
<li>
<span class="list-set-name">HIV Agents (Anti-HIV Agents)</span>;</li>
<li>
<span class="list-set-name">Nucleoside Reverse Transcriptase Inhibitor (NRTI)</span>;</li>
<li>
<span class="list-set-name">Nucleotide Reverse Transcriptase Inhibitor (NRTI)</span></li></ul></div>
<div class="block dop drugH1Div" id="F13168459"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Multiple tablet strengths exist and contain different amounts of emtricitabine and tenofovir. <b>International Considerations:</b> Tenofovir doses are expressed as tenofovir disoproxil fumarate, consistent with US labeling; in some other countries, dosing may be expressed as tenofovir disoproxil base. Tenofovir disoproxil fumarate 300 mg is equivalent to tenofovir disoproxil base 245 mg.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="54b359d7-24b9-4b96-9d31-710e220dc129">HIV-1 infection, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>HIV-1 infection, treatment:</b> Use in combination with another antiretroviral agent. Gene mutation and antiretroviral resistance patterns should be evaluated (refer to https://www.iasusa.org for more information) when necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents weighing ≥17 kg:</p>
<p style="text-indent:-2em;margin-left:6em;">17 to &lt;22 kg: Oral: One tablet (emtricitabine 100 mg/tenofovir disoproxil fumarate 150 mg) once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">22 to &lt;28 kg: Oral: One tablet (emtricitabine 133 mg/tenofovir disoproxil fumarate 200 mg) once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">28 to &lt;35 kg: Oral: One tablet (emtricitabine 167 mg/tenofovir disoproxil fumarate 250 mg) once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">≥35 kg: Oral: One tablet (emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) once daily.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c824a278-50cd-4850-b11e-cd825d73f9f9">HIV infection, postexposure prophylaxis, nonoccupational</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>HIV infection, postexposure</b>
<b> prophylaxis, nonoccupational (nPEP)</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.4']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.4'])">Ref</a></span>): Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents: Oral: One tablet (emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) once daily for 28 days in combination with other antiretroviral agents. Initiate therapy within 72 hours of exposure.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e248a7aa-c106-402d-a21a-b53738bf5486">HIV-1 infection, preexposure prophylaxis in uninfected high-risk individuals</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>HIV-1 infection, preexposure prophylaxis (PrEP) in uninfected high-risk individuals:</b>
<b>Note: </b>Patients should be confirmed HIV-negative immediately prior to initiation of therapy and screened again at least once every 3 months and upon diagnosis of any other sexually transmitted infections (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.3','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.3','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents weighing ≥35 kg: Oral: One tablet (emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) once daily.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51108461"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>HIV-1 infection, treatment:</b> Children and Adolescents weighing ≥17 kg: Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl ≥50 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &lt;50 mL/minute: There are no pediatric-specific recommendations; based on experience in adult patients, dosage adjustment suggested; use in hemodialysis is not recommended.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Preexposure prophylaxis: </b>Adolescents weighing ≥35 kg:</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl ≥60 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &lt;60 mL/minute: Use is not recommended.</p></div>
<div class="block dohp drugH1Div" id="F51108462"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, no dosing adjustments are necessary for tenofovir in hepatic impairment. No specific data is available on emtricitabine in hepatic impairment, but given its limited hepatic metabolism, the impact of liver impairment should be minimal; need for dose adjustment is unlikely.</p></div>
<div class="block doa drugH1Div" id="F164683"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="8527" href="/d/html/8527.html" rel="external">see "Tenofovir disoproxil fumarate and emtricitabine: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6208e4a3-52ad-48b4-8465-904f1785244c">HIV-1 infection, preexposure prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>HIV-1 infection, preexposure prophylaxis:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Persons who inject drugs (off-label use):</i>
<b>Oral:</b> One tablet (emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.3']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.3'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>HIV-uninfected individuals at high-risk for sexual acquisition:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Daily dosing schedule: <b>Oral:</b> One tablet (emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) once daily in combination with safe sex practices (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.3']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.3'])">Ref</a></span>). In men who have sex with men, some experts recommend initiating with a double dose (2 tablets [emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg <b>per tablet</b>]) on day 1, followed by 1 tablet once daily to reduce time to anticipated maximal protection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33052386']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33052386'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">On demand (2-1-1) dosing schedule (for use in men who have sex with men <b>only</b>) (off label): <b>Oral:</b> Two tablets (emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg <b>per tablet</b>) taken 2 to 24 hours (as close to 24 hours as possible) prior to sexual activity, 1 tablet 24 hours later, and 1 tablet 24 hours after that. In patients who initiate on demand therapy more than once within a week, only 1 tablet should be used for a loading dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.3','lexi-content-ref-33052386','lexi-content-ref-26624850']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.3','lexi-content-ref-33052386','lexi-content-ref-26624850'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="537f20ed-f39f-48de-b339-83c126bb5f9d">HIV-1 infection, postexposure prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>HIV-1 infection, postexposure prophylaxis (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Nonoccupational exposure:</i>
<b>Oral:</b> One tablet (emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) once daily for 28 days in combination with other antiretroviral agents. Initiate therapy within 72 hours of exposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.4']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.4'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Occupational exposure:</i>
<b>Oral:</b> One tablet (emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) once daily for 4 weeks with concomitant raltegravir. Initiate therapy as soon as possible after occupational exposure (and within 72 hours) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23917901']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23917901'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="54b359d7-24b9-4b96-9d31-710e220dc129">HIV-1 infection, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>HIV-1 infection, treatment:</b>
<b>Oral:</b> One tablet (emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) once daily in combination with other antiretroviral agents.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="61f04a2f-8f09-49e6-9832-b8cb7bf4617e">HIV-1/hepatitis B co-infection, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>HIV-1/hepatitis B co-infection, treatment (off-label use): Oral:</b> One tablet (emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) once daily in combination with other antiretroviral agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.5']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.5'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50992066"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>HIV-1 infection, treatment:</i></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> The tenofovir disoproxil fumarate component of this product is associated with proximal tubular injury, Fanconi syndrome, and progression of chronic kidney disease (CKD). Avoid use in patients with preexisting CKD (eGFR &lt;60 mL/minute/1.73 m<sup>2</sup>), especially if the patient has any proximal tubular impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25234519']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25234519'])">Ref</a></span>). If use cannot be avoided, the following dose adjustments are recommended:</p>
<p style="text-indent:-2em;margin-left:4em;">Manufacturer's labeling:</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl ≥50 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl 30 to 49 mL/minute: Increase interval to every 48 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl &lt;30 mL/minute: Not recommended.</p>
<p style="text-indent:-2em;margin-left:6em;">Hemodialysis, intermittent (thrice weekly): Not recommended.</p>
<p style="text-indent:-2em;margin-left:6em;">CRRT: Use of fixed dose combination is not recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>HIV-1 preexposure prophylaxis </i>
<i>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33052386','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33052386','lexi-content-ref-Manu.1'])">Ref</a></span>):</i></p>
<p style="text-indent:-2em;margin-left:4em;">CrCl ≥60 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &lt;60 mL/minute: Not recommended.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>HIV-1 postexposure prophylaxis </i>
<i>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23917901']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23917901'])">Ref</a></span>):</i></p>
<p style="text-indent:-2em;margin-left:4em;">eGFR ≥60 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">eGFR &lt;60 mL/minute/1.73 m<sup>2</sup>: Not recommended.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Acute kidney injury during treatment:</i> Infectious Diseases Society of America guidelines recommend discontinuing tenofovir (and substituting with alternative antiretroviral therapy) in HIV-infected patients who develop a decline in GFR (a &gt;25% decrease in GFR from baseline and to a level of &lt;60 mL/minute/1.73 m<sup>2</sup>) during use, particularly in presence of proximal tubular dysfunction (eg, euglycemic glycosuria, increased urinary phosphorus excretion and hypophosphatemia, proteinuria [new onset or worsening]) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25234519']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25234519'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50989383"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block arsc drugH1Div" id="F56806871"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Bone effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Tenofovir disoproxil fumarate (TDF) is associated with a larger <b>decreased bone mineral density </b>(BMD) in HIV-1 infected patients of all ages than in those not taking TDF (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32077867','lexi-content-ref-HHS.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32077867','lexi-content-ref-HHS.1'])">Ref</a></span>). The rate of bone loss slows after 1 to 2 years following initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31642586','lexi-content-ref-15249568','lexi-content-ref-32210458']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31642586','lexi-content-ref-15249568','lexi-content-ref-32210458'])">Ref</a></span>). TDF may be associated with in increased risk of <b>bone fracture</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28329090']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28329090'])">Ref</a></span>). When used as preexposure prophylaxis (PrEP), there is a smaller reduction in BMD (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32077867']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32077867'])">Ref</a></span>). Mean BMD returns to baseline levels within 12 to 18 months after TDF-based PrEP discontinuation in both hip and spine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28639995','lexi-content-ref-26866954']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28639995','lexi-content-ref-26866954'])">Ref</a></span>). TDF is also associated with bone loss (both absolute BMD and reduced Z-score) in children and adolescents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25760566','lexi-content-ref-18346519','lexi-content-ref-34139202']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25760566','lexi-content-ref-18346519','lexi-content-ref-34139202'])">Ref</a></span>). Patients with HIV aged ≥12 years treated with TDF are more likely to experience a &gt;4% decline in lumber spine BMD than those treated with placebo (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22301477']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22301477'])">Ref</a></span>). Those with sexual maturity ratings (SMR [formerly Tanner staging]) 1 to 2 may be at greater risk (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16291735']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16291735'])">Ref</a></span>). Bone loss partially recovers after discontinuation in children and adolescents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31179503','lexi-content-ref-16291735']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31179503','lexi-content-ref-16291735'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Time-related; not clearly established. Tenofovir inhibition of calcium-sensing receptors in the parathyroid (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29136775']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29136775'])">Ref</a></span>) may increase PTH levels (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31269294']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31269294'])">Ref</a></span>). It has been proposed that PTH levels accelerate bone remodeling which, combined with persistent HIV-associated demineralization in persons with HIV, results in increased osteoid volume (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31269294']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31269294'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; markers of bone resorption are apparent within 12 weeks after beginning TDF (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34353266']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34353266'])">Ref</a></span>). Reductions in BMD are observed during the first 1 to 2 years following initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28329090','lexi-content-ref-21606537','lexi-content-ref-26866954']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28329090','lexi-content-ref-21606537','lexi-content-ref-26866954'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors (for bone loss and/or fracture):</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Treatment duration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28329090','lexi-content-ref-21606537','lexi-content-ref-26866954']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28329090','lexi-content-ref-21606537','lexi-content-ref-26866954'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Females (especially postmenopausal) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32210458','lexi-content-ref-HHS.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32210458','lexi-content-ref-HHS.1'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Transgender (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.1'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• White race (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28329090']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28329090'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Prior fracture (and patients at risk for recurrent falls) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28329090','lexi-content-ref-HHS.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28329090','lexi-content-ref-HHS.1'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Prolonged systemic corticosteroid use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Medroxyprogesterone use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Smoking (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Early stages of puberty (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28329090']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28329090'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Vitamin D insufficiency/deficiency (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Low BMI (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28329090','lexi-content-ref-HHS.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28329090','lexi-content-ref-HHS.2'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Lack of weight-bearing exercise (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Cardiovascular disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28329090']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28329090'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Longer duration and greater severity of HIV disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2','lexi-content-ref-34856908']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2','lexi-content-ref-34856908'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• CD4<sup>+</sup> cell count &lt;350 cells/mm<sup>3</sup> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32210458']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32210458'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Pharmacologic boosters (cobicistat or ritonavir) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.1'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• IV Drug use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28329090']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28329090'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Lipodystrophy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Recent non-AIDS cancer (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28329090']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28329090'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Kidney injury</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">The tenofovir disoproxil fumarate (TDF) component is associated with multiple renal syndromes. Toxic acute tubular necroses manifest as acute kidney injury, chronic interstitial nephritis as chronic kidney disease, and renal tubulopathies as <b>Fanconi syndrome </b>and rarely nephrogenic diabetes insipidus (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25234519','lexi-content-ref-21076445']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25234519','lexi-content-ref-21076445'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Acute kidney injury (AKI): TDF is associated with AKI, with the majority of cases meeting the risk definition according to the RIFLE classification or AKIN Stage I (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23739150']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23739150'])">Ref</a></span>). Kidney function improves over months after TDF discontinuation but does not reverse completely in all cases (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20173649','lexi-content-ref-23739150','lexi-content-ref-16355343']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20173649','lexi-content-ref-23739150','lexi-content-ref-16355343'])">Ref</a></span>). It is reported to recur on rechallenge (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16355343']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16355343'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Chronic kidney disease (CKD): TDF reduces estimated glomerular filtration rate (eGFR) by ~4 mL/minute compared with non–TDF-containing regimens (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31834000','lexi-content-ref-20673002']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31834000','lexi-content-ref-20673002'])">Ref</a></span>) and this may progress to CKD (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21566114','lexi-content-ref-20523203','lexi-content-ref-22313955']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21566114','lexi-content-ref-20523203','lexi-content-ref-22313955'])">Ref</a></span>). A smaller reduction in eGFR occurs when used for preexposure prophylaxis (PrEP) compared with placebo (eg, 1.59 mL/minute in PARTNERS) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25531343']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25531343'])">Ref</a></span>). When used for PrEP, eGFR returns to baseline 4 to 8 weeks after discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26914909']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26914909'])">Ref</a></span>) but may not return to baseline in some cases (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24585896','lexi-content-ref-35143730']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24585896','lexi-content-ref-35143730'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Fanconi syndrome (FS): TDF is associated with partial or, more rarely, complete FS (proximal renal tubular acidosis with a normal anion gap metabolic acidosis, hypophosphatemia and osteomalacia with renal phosphate wasting, hypokalemia, hypouricemia, glycosuria with normal blood glucose, and aminoaciduria) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24651857','lexi-content-ref-25234519']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24651857','lexi-content-ref-25234519'])">Ref</a></span>). FS has resulted in fatal cases (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18260800','lexi-content-ref-23430209']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18260800','lexi-content-ref-23430209'])">Ref</a></span>). In most patients, proximal tubulopathy resolves within 2 months of TDF discontinuation, but CrCl takes longer to recover and may not return to baseline (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24651857','lexi-content-ref-28130143','lexi-content-ref-23430209']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24651857','lexi-content-ref-28130143','lexi-content-ref-23430209'])">Ref</a></span>). Osteomalacia resolved within 14 weeks of discontinuing TDF in one case report (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34073672']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34073672'])">Ref</a></span>). FS may present as bone pain as a manifestation of osteomalacia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34073672','lexi-content-ref-35132821']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34073672','lexi-content-ref-35132821'])">Ref</a></span>). FS occurs less frequently when used for PrEP (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31794523','lexi-content-ref-34608820']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31794523','lexi-content-ref-34608820'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose- and time-related; inhibition of DNA polymerase gamma results in mitochondrial DNA (mtDNA) depletion, mitochondrial dysfunction, and cell toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20811330']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20811330'])">Ref</a></span>). Proximal tubule epithelial cells are particularly susceptible (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20811330']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20811330'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i></p>
<p style="text-indent:-2em;margin-left:6em;">AKI: Varied; mean of 6 months (range, 3 to 16.5 months) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23739150']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23739150'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">CKD: Varied; an eGFR decline is seen within 1 month of initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25531343']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25531343'])">Ref</a></span>). Significant (stage 3 or greater) CKD has occurred at a median of 45 weeks (interquartile range, 11 to 137 weeks) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22824630']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22824630'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">FS: Varied; diagnosis ranged from 3.9 months to 11 years in a representative case series (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28130143']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28130143'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">AKI:</p>
<p style="text-indent:-2em;margin-left:8em;">• Lower baseline SCr (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23739150']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23739150'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Higher baseline eGFR (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23739150']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23739150'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Concurrent protease inhibitor (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23739150']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23739150'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Concurrent sulfamethoxazole/trimethoprim (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23739150']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23739150'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Concurrent non-steroidal anti-inflammatory drugs (NSAIDs), particularly diclofenac (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23980564']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23980564'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Lower baseline CD4 cell count (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23739150']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23739150'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Higher baseline viral load (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23739150']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23739150'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">CKD:</p>
<p style="text-indent:-2em;margin-left:8em;">• Cumulative TDF exposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20523203']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20523203'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Higher preexisting risk of CKD (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33247876']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33247876'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Preexisting kidney disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23739150']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23739150'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Lower eGFR at initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20523203']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20523203'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Prior AKI (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23739150']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23739150'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Concurrent atazanavir/lopinavir or ritonavir (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25234519','lexi-content-ref-20523203']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25234519','lexi-content-ref-20523203'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Concurrent NSAIDs, particularly diclofenac (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26401025']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26401025'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Hypertension (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23739150']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23739150'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Older age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20523203']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20523203'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Hepatitis C coinfection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20523203']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20523203'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Lower CD4 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20523203']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20523203'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Higher viral load (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22824630']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22824630'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">FS:</p>
<p style="text-indent:-2em;margin-left:8em;">• Longer TDF treatment duration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28130143']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28130143'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Reduced CrCl before TDF initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24651857']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24651857'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Concurrent cobicistat or ritonavir (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28764611','lexi-content-ref-23896476']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28764611','lexi-content-ref-23896476'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Previous or concurrent lopinavir/ritonavir (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24651857']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24651857'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Coronary artery disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21808434']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21808434'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Diabetes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21808434']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21808434'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Low body weight (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21808434']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21808434'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Older age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28130143']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28130143'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Hepatitis C coinfection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21808434']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21808434'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Hypertension (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21808434']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21808434'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• White race (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28130143']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28130143'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Longer HIV duration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24651857','lexi-content-ref-21808434']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24651857','lexi-content-ref-21808434'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Lower nadir CD4 counts (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28130143']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28130143'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Prior AIDS diagnosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28130143']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28130143'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• ABCC2 &amp; ABCC10 polymorphism (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33850298','lexi-content-ref-17083032']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33850298','lexi-content-ref-17083032'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F164663"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adult monotherapy studies for HIV-1 pre-exposure prophylaxis. Also see individual agents.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Neuromuscular &amp; skeletal: Decreased bone mineral density (13%)<span class="lexi-table-link-container"> (<a aria-label="Decreased Bone Mineral Density table link" class="lexi-table-link" data-table-id="lexi-content-decreased-bone-mineral-density" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-decreased-bone-mineral-density')">table 1</a>)</span><span class="table-link" style="display:none;">Decreased Bone Mineral Density</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Decreased Bone Mineral Density" frame="border" id="lexi-content-decreased-bone-mineral-density" rules="all">
<caption style="text-align:center;">
<b>Emtricitabine and Tenofovir Disoproxil Fumarate: Adverse Reaction: Decreased Bone Mineral Density</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Emtricitabine and Tenofovir Disoproxil Fumarate)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">13%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">≥5% bone mineral density loss at the spine during treatment</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Abnormal phosphorus levels (&lt;2.0 mg/dL: 10%), weight loss (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Decreased neutrophils (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache (7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Bone fracture (2%)<span class="lexi-table-link-container"> (<a aria-label="Bone Fracture table link" class="lexi-table-link" data-table-id="lexi-content-bone-fracture" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-bone-fracture')">table 2</a>)</span><span class="table-link" style="display:none;">Bone Fracture</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Bone Fracture" frame="border" id="lexi-content-bone-fracture" rules="all">
<caption style="text-align:center;">
<b>Emtricitabine and Tenofovir Disoproxil Fumarate: Adverse Reaction: Bone Fracture</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Emtricitabine and Tenofovir Disoproxil Fumarate)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%: Genitourinary: Glycosuria, proteinuria</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Hepatic: Exacerbation of hepatitis B (following discontinuation)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Immune reconstitution syndrome</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Fanconi syndrome (Rao 2021)</p></div>
<div class="block coi drugH1Div" id="F164674"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">As preexposure prophylaxis in patients with unknown or HIV-1 positive status</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Hypersensitivity to emtricitabine, tenofovir, or any component of the formulation</p></div>
<div class="block war drugH1Div" id="F164661"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Immune reconstitution syndrome: Patients may develop immune reconstitution syndrome resulting in the occurrence of an inflammatory response to an indolent or residual opportunistic infection during initial HIV treatment or activation of autoimmune disorders (eg, Graves disease, polymyositis, Guillain-Barré syndrome, autoimmune hepatitis) later in therapy; further evaluation and treatment may be required.</p>
<p style="text-indent:-2em;margin-left:4em;">• Lactic acidosis/hepatomegaly: Lactic acidosis and severe hepatomegaly with steatosis, sometimes fatal, have been reported with use of nucleoside analogues, alone or in combination with other antiretrovirals. Suspend treatment in any patient who develops clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity (marked transaminase elevation may/may not accompany hepatomegaly and steatosis).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Comprehensive prevention program: Preexposure prophylaxis (PrEP) should be accompanied by a comprehensive HIV-1 prevention program (eg, risk reduction counseling, access to condoms), with particular emphasis on medication adherence. In addition, regular monitoring (eg, HIV status of patient and partner(s), risk behavior, adherence, adverse effects, sexually transmitted infections that facilitate HIV-1 transmission) is highly recommended. Time from initiation of therapy to maximal protection against HIV-1 is unknown.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment; see "Dosing in Altered Kidney Function" for additional information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concurrent drug therapy issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Duplicate therapy: Do not use concurrently with emtricitabine, lamivudine, tenofovir disoproxil fumarate, tenofovir alafenamide, or any combination of these drugs.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878442"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Emtricitabine-associated hyperpigmentation may occur at a higher frequency in pediatric patients compared to adults (children: 32%; adults: 2% to 6%).</p></div>
<div class="block foc drugH1Div" id="F164669"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Truvada: Emtricitabine 100 mg and tenofovir disoproxil fumarate 150 mg, Emtricitabine 133 mg and tenofovir disoproxil fumarate 200 mg, Emtricitabine 167 mg and tenofovir disoproxil fumarate 250 mg, Emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg [contains fd&amp;c blue #2 (indigo carm) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: Emtricitabine 100 mg and tenofovir disoproxil fumarate 150 mg, Emtricitabine 133 mg and tenofovir disoproxil fumarate 200 mg, Emtricitabine 167 mg and tenofovir disoproxil fumarate 250 mg, Emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg</p></div>
<div class="block geq drugH1Div" id="F164659"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F3422225"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Emtricitabine-Tenofovir DF Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100-150 mg (per each): $70.01</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">133-200 mg (per each): $70.01</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">167-250 mg (per each): $70.01</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200-300 mg (per each): $2.34 - $70.01</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Truvada Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100-150 mg (per each): $73.69</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">133-200 mg (per each): $73.69</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">167-250 mg (per each): $73.69</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200-300 mg (per each): $73.69</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F53981867"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Truvada: Emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg [contains fd&amp;c blue #2 (indigo carm) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: Emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg</p></div>
<div class="block adip drugH1Div" id="F53566328"><span class="drugH1">Additional Information</span>
<p style="text-indent:0em;display:inline">Emtricitabine is the (-) enantiomer of 2', 3'-dideoxy-5-fluoro-3'-thiacytidine (FTC), a fluorinated derivative of lamivudine.</p>
<p style="text-indent:0em;margin-top:2em;">Mutation in the HIV reverse transcriptase gene at codon 184, M184V/I (ie, substitution of methionine by valine or isoleucine) is associated with resistance to emtricitabine. Emtricitabine-resistant isolates (M184V/I) are cross-resistant to lamivudine and zalcitabine. HIV-1 isolates containing the K65R mutation show reduced susceptibility to emtricitabine.</p></div>
<div class="block admp drugH1Div" id="F52612678"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: May be administered without regard to food</p></div>
<div class="block adm drugH1Div" id="F164671"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral:</b> May be administered with or without food.</p></div>
<div class="block sts drugH1Div" id="F164678"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store tablets at 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Dispense only in original container. Once bottle is opened, discard any remaining tablets after 6 weeks.</p></div>
<div class="block meg drugH1Div" id="F14633101"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and at <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F021752Orig1s063lbl.pdf%23page%3D35&amp;token=iVorETv%2F6K54C%2BsWKUEeTCLRelvte50g5q71PSnukMB0ZvL9reecWNQnGhuE5yurVejmyAHBZ1rPFE0NfmjiuNre0gKV4rQrzL0wLauIHO6NMR2B4fD7xyyt50Indu4g&amp;TOPIC_ID=13013" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021752Orig1s063lbl.pdf#page=35</a>, must be dispensed with this medication.</p></div>
<div class="block usep drugH1Div" id="F53566652"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of HIV-1 infection in combination with other antiretroviral agents (FDA approved in pediatric patients weighing ≥17 kg and adults); <b>Note:</b> HIV regimens consisting of 3 antiretroviral agents from at least 2 classes are strongly recommended; preexposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in at-risk individuals (FDA approved in adolescents weighing ≥35 kg and adults); has also been used for HIV-1 nonoccupational postexposure prophylaxis (nPEP).</p></div>
<div class="block cyt drugH1Div" id="F13299259"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">Refer to individual components.</p></div>
<div class="block dri drugH1Div" id="F164664"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Acyclovir-Valacyclovir: May increase the serum concentration of Tenofovir Products. Tenofovir Products may increase the serum concentration of Acyclovir-Valacyclovir.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Adefovir: May diminish the therapeutic effect of Tenofovir Products. Adefovir may increase the serum concentration of Tenofovir Products. Tenofovir Products may increase the serum concentration of Adefovir.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aminoglycosides: May increase the serum concentration of Tenofovir Products. Tenofovir Products may increase the serum concentration of Aminoglycosides.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aminosalicylic Acid: May decrease the serum concentration of Tenofovir Disoproxil Fumarate.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Asciminib: May increase the serum concentration of BCRP/ABCG2 Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atazanavir: Tenofovir Disoproxil Fumarate may decrease the serum concentration of Atazanavir. Atazanavir may increase the serum concentration of Tenofovir Disoproxil Fumarate.  Management: Use boosted atazanavir in adults; give combo (atazanavir/ritonavir or atazanavir/cobicistat with tenofovir) as a single daily dose with food. Pediatric patients, pregnant patients, and use of H2-blockers require dose changes. See Lexi Interact monograph.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Betibeglogene Autotemcel: Antiretroviral Agents may diminish the therapeutic effect of Betibeglogene Autotemcel. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cabozantinib: MRP2 Inhibitors may increase the serum concentration of Cabozantinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cidofovir: May increase the serum concentration of Tenofovir Products. Tenofovir Products may increase the serum concentration of Cidofovir.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Agents that Undergo Intracellular Phosphorylation may diminish the therapeutic effect of Cladribine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cobicistat: Tenofovir Disoproxil Fumarate may enhance the adverse/toxic effect of Cobicistat. More specifically, cobicistat may impair proper tenofovir disoproxil fumarate monitoring and dosing. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Darolutamide: May increase the serum concentration of BCRP/ABCG2 Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Darunavir: Tenofovir Disoproxil Fumarate may increase the serum concentration of Darunavir. Darunavir may increase the serum concentration of Tenofovir Disoproxil Fumarate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Didanosine: Tenofovir Disoproxil Fumarate may diminish the therapeutic effect of Didanosine. Tenofovir Disoproxil Fumarate may increase the serum concentration of Didanosine.  Management: Avoid use of tenofovir disoproxil fumarate and didanosine when possible. If combined in adults with CrCL greater than 60 mL/min, decrease didanosine to 250 mg daily if 60 kg or more or to 200 mg if less than 60 kg. Avoid if CrCL is less than 60 mL/min.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elacestrant: May increase the serum concentration of BCRP/ABCG2 Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elivaldogene Autotemcel: Antiretroviral Agents may diminish the therapeutic effect of Elivaldogene Autotemcel.  Management: Avoid use of antiretroviral medications for at least one month, or for the amount of time required for elimination of the retroviral medication, prior to stem cell mobilization and until the all apheresis cycles are finished<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eltrombopag: May increase the serum concentration of BCRP/ABCG2 Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Encorafenib: May increase the serum concentration of BCRP/ABCG2 Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Futibatinib: May increase the serum concentration of BCRP/ABCG2 Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ganciclovir-Valganciclovir: Tenofovir Products may increase the serum concentration of Ganciclovir-Valganciclovir. Ganciclovir-Valganciclovir may increase the serum concentration of Tenofovir Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gilteritinib: May increase the serum concentration of BCRP/ABCG2 Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ledipasvir: May increase the serum concentration of Tenofovir Disoproxil Fumarate. Management: Avoid this combination if TDF is used as part of the elvitegravir/cobicistat/emtricitabine/TDF product. Consider alternatives when TDF is used with a ritonavir or cobicistat boosted protease inhibitor. Monitor for increased TDF toxicities if combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leflunomide: May increase the serum concentration of BCRP/ABCG2 Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leniolisib: May increase the serum concentration of BCRP/ABCG2 Substrates (Clinically Relevant with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lopinavir: May enhance the nephrotoxic effect of Tenofovir Disoproxil Fumarate. Lopinavir may increase the serum concentration of Tenofovir Disoproxil Fumarate.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lovotibeglogene Autotemcel: Antiretroviral Agents may diminish the therapeutic effect of Lovotibeglogene Autotemcel. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lumacaftor and Ivacaftor: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates (High risk with Inhibitors or Inducers). Lumacaftor and Ivacaftor may decrease the serum concentration of P-glycoprotein/ABCB1 Substrates (High risk with Inhibitors or Inducers).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents: May enhance the nephrotoxic effect of Tenofovir Products. Management: Seek alternatives to these combinations whenever possible. Avoid use of tenofovir with multiple NSAIDs or any NSAID given at a high dose due to a potential risk of acute renal failure. Diclofenac appears to confer the most risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (Topical): May enhance the nephrotoxic effect of Tenofovir Products.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orlistat: May decrease the serum concentration of Antiretroviral Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Osimertinib: May increase the serum concentration of BCRP/ABCG2 Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oteseconazole: May increase the serum concentration of BCRP/ABCG2 Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pacritinib: May increase the serum concentration of BCRP/ABCG2 Substrates (Clinically Relevant with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of Tenofovir Disoproxil Fumarate.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pretomanid: May increase the serum concentration of BCRP/ABCG2 Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Regorafenib: May increase the serum concentration of BCRP/ABCG2 Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rolapitant: May increase the serum concentration of BCRP/ABCG2 Substrates (Clinically Relevant with Inhibitors). Management: Monitor patients receiving rolapitant for increased exposure to and/or effects of BCRP/ABCG2 substrates.  Use the lowest effective rosuvastatin dose when used in combination with rolapitant.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sparsentan: May increase the serum concentration of BCRP/ABCG2 Substrates (Clinically Relevant with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): Tenofovir Products may enhance the nephrotoxic effect of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tafamidis: May increase the serum concentration of BCRP/ABCG2 Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Taurursodiol: May increase the serum concentration of BCRP/ABCG2 Substrates (Clinically Relevant with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tedizolid: May increase the serum concentration of BCRP/ABCG2 Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Teriflunomide: May increase the serum concentration of BCRP/ABCG2 Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tipranavir: Tenofovir Disoproxil Fumarate may decrease the serum concentration of Tipranavir. Tipranavir may decrease the serum concentration of Tenofovir Disoproxil Fumarate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Voxilaprevir: Tenofovir Disoproxil Fumarate may increase the serum concentration of Voxilaprevir. Voxilaprevir may increase the serum concentration of Tenofovir Disoproxil Fumarate. <i> Risk C: Monitor therapy</i></p></div>
<div class="block foi drugH1Div" id="F164679"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">See individual agents.</p></div>
<div class="block dic drugH1Div" id="F164677"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Consider calcium and vitamin D supplementation in patients with history of bone fracture or osteopenia.</p></div>
<div class="block rep_considerations drugH1Div" id="F49661578"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">The Health and Human Services (HHS) perinatal HIV guidelines consider this a preferred combination for patients with HIV who are not yet pregnant but are trying to conceive.</p>
<p style="text-indent:0em;margin-top:2em;">This combination is recommended for pre-exposure prophylaxis (PrEP) in patients at risk for HIV infection who are planning a pregnancy. The partner without HIV should begin therapy 20 days prior to attempting conception. Up to 20 days of therapy are required to achieve protective drug concentrations in cervicovaginal tissue, therefore continued use of condoms to prevent HIV exposure is recommended during this time. PrEP should continue for 28 days after attempting conception or condomless sex exposure. Episodic or on demand dosing is not effective for prevention of HIV via vaginal exposure. Pregnancy testing should be done at baseline, then as indicated (HHS [perinatal] 2023).</p>
<p style="text-indent:0em;margin-top:2em;">Refer to individual monographs for additional information.</p></div>
<div class="block pri drugH1Div" id="F164675"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">The Health and Human Services (HHS) perinatal HIV guidelines consider emtricitabine with tenofovir disoproxil fumarate to be a preferred nucleoside reverse transcriptase inhibitor backbone for initial therapy in antiretroviral-naive pregnant patients. In addition, this combination is preferred for use in pregnant patients with HIV who have had antiretroviral therapy (ART) in the past but are restarting, or who require a new ART regimen (due to poor tolerance or poor virologic response of current regimen). Patients who become pregnant while taking this combination may continue if viral suppression is effective and the regimen is well tolerated.</p>
<p style="text-indent:0em;margin-top:2em;">This combination is recommended for pre-exposure prophylaxis (PrEP) in uninfected patients at risk for HIV infection who are pregnant; if started prior to conception, it may be continued during pregnancy. Emtricitabine and tenofovir disoproxil fumarate are recommended as part of a preferred regimen when early (acute/recent) HIV infection is detected during pregnancy; genotyping may be required if the person had prior use of long acting cabotegravir for PrEP.</p>
<p style="text-indent:0em;margin-top:2em;">The HHS perinatal guidelines also recommend emtricitabine plus tenofovir disoproxil fumarate as a component of regimens for HIV/hepatitis B virus–coinfected patients who are pregnant (HHS [perinatal] 2023).</p>
<p style="text-indent:0em;margin-top:2em;">Refer to individual monographs for additional information.</p></div>
<div class="block mopp drugH1Div" id="F53566646"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>HIV: Preexposure prophylaxis (PrEP):</b> General recommendations: Refer to current guidelines for complete monitoring recommendations for patients receiving PrEP. Assessment should include risk behaviors and HIV testing (prior to initiation, every 3 months, if recent exposures are suspected, upon diagnosis of other sexually transmitted infections, and if clinical symptoms consistent with acute HIV infection are present). Monitor CrCl every 12 months, or more frequently in some patients as clinically appropriate.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>HIV: Treatment:</b> General recommendations: Management of HIV infection requires extensive monitoring; refer to current guidelines (<a href="/external-redirect?target_url=https%3A%2F%2Fclinicalinfo.hiv.gov%2Fen%2Fguidelines&amp;token=nbsXe3i4qfUea5RCPRHtOXmm4jIHQPk10%2Bpt6G4BSzQwKJFM0Nvf8hDv6AkFR6Vg&amp;TOPIC_ID=13013" target="_blank">https://clinicalinfo.hiv.gov/en/guidelines</a>) for additional guidance. Antiretroviral (ARV) drug-resistance testing is recommended before initiation of therapy in treatment-naive patients. After initiation of or change in ARV therapy regimen, pediatric patients should be evaluated for clinical adverse effects and treatment adherence at 1 to 2 weeks, and laboratory testing for drug toxicity should occur at 2 to 4 weeks; monitor for therapy adherence, effectiveness, and toxicities every 3 to 4 months.</p>
<p style="text-indent:-2em;margin-left:4em;">Drug-specific monitoring: Frequency may vary based on several factors including age, concomitant therapy, and clinical response; refer to current guidelines for additional information.</p>
<p style="text-indent:-2em;margin-left:6em;">Screen for hepatitis B prior to starting therapy (in patients who previously demonstrated no immunity to hepatitis B). For patients with hepatitis B coinfection, monitor hepatic function and hepatitis B viral load for several months after therapy with tenofovir is stopped.</p>
<p style="text-indent:-2em;margin-left:6em;">Serum electrolytes (including anion gap), 25-OH-vitamin D levels, serum phosphate, SCr, lipid profiles, urine protein and glucose and/or urinalysis, serum lactate (if clinical presentation indicates need). Assess nutritional intake (calcium, vitamin D, and total calories). Consider obtaining a dual-energy x-ray absorptiometry scan in patients with additional risk factors for decreased bone density (eg, cerebral palsy, additional medications) (HHS [pediatric] 2022).</p>
<p style="text-indent:-2em;margin-left:6em;">Urine albumin to protein ratio may be helpful in identifying the nonalbumin proteinuria seen in tenofovir disoproxil fumarate-associated nephrotoxicity (HHS [pediatric] 2022).</p></div>
<div class="block pha drugH1Div" id="F164660"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Nucleoside and nucleotide reverse transcriptase inhibitor combination; emtricitabine is a cytidine analogue while tenofovir is an analog of adenosine 5'-monophosphate. Each drug interferes with HIV viral RNA dependent DNA polymerase resulting in inhibition of viral replication.</p></div>
<div class="block phk drugH1Div" id="F164673"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">Refer to individual monographs.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F4301432"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Calprega</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Luviren pro</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-31794523">
<a name="31794523"></a>Ascher SB, Scherzer R, Estrella MM, et al. HIV preexposure prophylaxis with tenofovir disoproxil fumarate/emtricitabine and changes in kidney function and tubular health. <i>AIDS</i>. 2020;34(5):699-706. doi:10.1097/QAD.0000000000002456<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tenofovir-disoproxil-fumarate-and-emtricitabine-pediatric-drug-information/abstract-text/31794523/pubmed" id="31794523" target="_blank">31794523</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34353266">
<a name="34353266"></a>Atencio P, Conesa-Buendía FM, Cabello-Ubeda A, et al. Bone deleterious effects of different NRTIs in treatment-naïve HIV patients after 12 and 48 weeks of treatment. <i>Curr HIV Res</i>. 2021;19(5):434-447. doi:10.2174/1570162X19666210805094434<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tenofovir-disoproxil-fumarate-and-emtricitabine-pediatric-drug-information/abstract-text/34353266/pubmed" id="34353266" target="_blank">34353266</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25760566">
<a name="25760566"></a>Aurpibul L, Cressey TR, Sricharoenchai S, et al. Efficacy, safety and pharmacokinetics of tenofovir disoproxil fumarate in virologic-suppressed HIV-infected children using weight-band dosing. <i>Pediatr Infect Dis J</i>. 2015;34(4):392-397. doi:10.1097/INF.0000000000000633<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tenofovir-disoproxil-fumarate-and-emtricitabine-pediatric-drug-information/abstract-text/25760566/pubmed" id="25760566" target="_blank">25760566</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22784037">
<a name="22784037"></a>Baeten JM, Donnell D, Ndase P, et al. Antiretroviral Prophylaxis for HIV Prevention in Heterosexual Men and Women. <i>N Engl J Med.</i> 2012;367(5):399-410.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tenofovir-disoproxil-fumarate-and-emtricitabine-pediatric-drug-information/abstract-text/22784037/pubmed" id="22784037" target="_blank">22784037</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32077867">
<a name="32077867"></a>Baranek B, Wang S, Cheung AM, Mishra S, Tan DH. The effect of tenofovir disoproxil fumarate on bone mineral density: a systematic review and meta-analysis. <i>Antivir Ther</i>. 2020;25(1):21-32. doi:10.3851/IMP3346<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tenofovir-disoproxil-fumarate-and-emtricitabine-pediatric-drug-information/abstract-text/32077867/pubmed" id="32077867" target="_blank">32077867</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23980564">
<a name="23980564"></a>Bickel M, Khaykin P, Stephan C, et al. Acute kidney injury caused by tenofovir disoproxil fumarate and diclofenac co-administration. <i>HIV Med</i>. 2013;14(10):633-638. doi:10.1111/hiv.12072<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tenofovir-disoproxil-fumarate-and-emtricitabine-pediatric-drug-information/abstract-text/23980564/pubmed" id="23980564" target="_blank">23980564</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28329090">
<a name="28329090"></a>Borges ÁH, Hoy J, Florence E, et al. Antiretrovirals, fractures, and osteonecrosis in a large international HIV cohort. <i>Clin Infect Dis</i>. 2017;64(10):1413-1421. doi:10.1093/cid/cix167<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tenofovir-disoproxil-fumarate-and-emtricitabine-pediatric-drug-information/abstract-text/28329090/pubmed" id="28329090" target="_blank">28329090</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31834000">
<a name="31834000"></a>Cahn P, Madero JS, Arribas JR, et al. Durable efficacy of dolutegravir plus lamivudine in antiretroviral treatment-naive adults with HIV-1 infection: 96-week results from the GEMINI-1 and GEMINI-2 randomized clinical trials. <i>J Acquir Immune Defic Syndr</i>. 2020;83(3):310-318. doi:10.1097/QAI.0000000000002275<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tenofovir-disoproxil-fumarate-and-emtricitabine-pediatric-drug-information/abstract-text/31834000/pubmed" id="31834000" target="_blank">31834000</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31642586">
<a name="31642586"></a>Carr A, Grund B, Schwartz AV, et al. The rate of bone loss slows after 1-2 years of initial antiretroviral therapy: final results of the Strategic Timing of Antiretroviral Therapy (START) bone mineral density substudy. <i>HIV Med</i>. 2020;21(1):64-70. doi:10.1111/hiv.12796<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tenofovir-disoproxil-fumarate-and-emtricitabine-pediatric-drug-information/abstract-text/31642586/pubmed" id="31642586" target="_blank">31642586</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.1">
<a name="CDC.1"></a>Centers for Disease Control and Prevention (CDC), US Department of Health and Human Services (HHS). Updated guidelines for antiretroviral postexposure prophylaxis after sexual, injection drug use, or other nonoccupational exposure to HIV—United States, 2016. <a href="https://stacks.cdc.gov/view/cdc/38856" target="_blank">https://stacks.cdc.gov/view/cdc/38856</a>. Published April 18, 2016. Accessed July 11, 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.3">
<a name="CDC.3"></a>Centers for Disease Control and Prevention (CDC), US Public Health Service. Preexposure prophylaxis for the prevention of HIV infection in the United States—2021 update: a clinical practice guideline. <a href="https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2021.pdf" target="_blank">https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2021.pdf</a>. Published December 2021. Accessed June 14, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33850298">
<a name="33850298"></a>Cheli S, Baldelli S, De Silvestri A, et al. ABCC4 single-nucleotide polymorphisms as markers of tenofovir disoproxil fumarate-induced kidney impairment. <i>Pharmacogenomics J</i>. 2021;21(5):586-593. doi:10.1038/s41397-021-00235-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tenofovir-disoproxil-fumarate-and-emtricitabine-pediatric-drug-information/abstract-text/33850298/pubmed" id="33850298" target="_blank">33850298</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20673002">
<a name="20673002"></a>Cooper RD, Wiebe N, Smith N, Keiser P, Naicker S, Tonelli M. Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. <i>Clin Infect Dis</i>. 2010;51(5):496-505. doi:10.1086/655681<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tenofovir-disoproxil-fumarate-and-emtricitabine-pediatric-drug-information/abstract-text/20673002/pubmed" id="20673002" target="_blank">20673002</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22301477">
<a name="22301477"></a>Della Negra M, de Carvalho AP, de Aquino MZ, et al. A randomized study of tenofovir disoproxil fumarate in treatment-experienced HIV-1 infected adolescents. <i>Pediatr Infect Dis J</i>. 2012;31(5):469-473. doi:10.1097/INF.0b013e31824bf239<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tenofovir-disoproxil-fumarate-and-emtricitabine-pediatric-drug-information/abstract-text/22301477/pubmed" id="22301477" target="_blank">22301477</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21566114">
<a name="21566114"></a>Flandre P, Pugliese P, Cuzin L, et al. Risk factors of chronic kidney disease in HIV-infected patients. <i>Clin J Am Soc Nephrol</i>. 2011;6(7):1700-1707. doi:10.2215/CJN.09191010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tenofovir-disoproxil-fumarate-and-emtricitabine-pediatric-drug-information/abstract-text/21566114/pubmed" id="21566114" target="_blank">21566114</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15249568">
<a name="15249568"></a>Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. <i>JAMA</i>. 2004;292(2):191-201. doi:10.1001/jama.292.2.191<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tenofovir-disoproxil-fumarate-and-emtricitabine-pediatric-drug-information/abstract-text/15249568/pubmed" id="15249568" target="_blank">15249568</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28639995">
<a name="28639995"></a>Glidden DV, Mulligan K, McMahan V, et al. Brief report: recovery of bone mineral density after discontinuation of tenofovir-based HIV pre-exposure prophylaxis. <i>J Acquir Immune Defic Syndr</i>. 2017;76(2):177-182. doi:10.1097/QAI.0000000000001475<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tenofovir-disoproxil-fumarate-and-emtricitabine-pediatric-drug-information/abstract-text/28639995/pubmed" id="28639995" target="_blank">28639995</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21091279">
<a name="21091279"></a>Grant RM, Lama JR, Anderson PL, et a. Pre-exposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex With Men. <i>N Engl J Med.</i> 2010;363(27):2587-2599.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tenofovir-disoproxil-fumarate-and-emtricitabine-pediatric-drug-information/abstract-text/21091279/pubmed" id="21091279" target="_blank">21091279</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24651857">
<a name="24651857"></a>Gupta SK, Anderson AM, Ebrahimi R, et al. Fanconi syndrome accompanied by renal function decline with tenofovir disoproxil fumarate: a prospective, case-control study of predictors and resolution in HIV-infected patients. <i>PLoS One</i>. 2014;9(3):e92717. doi:10.1371/journal.pone.0092717<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tenofovir-disoproxil-fumarate-and-emtricitabine-pediatric-drug-information/abstract-text/24651857/pubmed" id="24651857" target="_blank">24651857</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18260800">
<a name="18260800"></a>Gupta SK. Tenofovir-associated Fanconi syndrome: review of the FDA adverse event reporting system. <i>AIDS Patient Care STDS</i>. 2008;22(2):99-103. doi:10.1089/apc.2007.0052<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tenofovir-disoproxil-fumarate-and-emtricitabine-pediatric-drug-information/abstract-text/18260800/pubmed" id="18260800" target="_blank">18260800</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28130143">
<a name="28130143"></a>Hamzah L, Jose S, Booth JW, et al. Treatment-limiting renal tubulopathy in patients treated with tenofovir disoproxil fumarate. <i>J Infect</i>. 2017;74(5):492-500. doi:10.1016/j.jinf.2017.01.010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tenofovir-disoproxil-fumarate-and-emtricitabine-pediatric-drug-information/abstract-text/28130143/pubmed" id="28130143" target="_blank">28130143</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32210458">
<a name="32210458"></a>Han WM, Wattanachanya L, Apornpong T, et al. Bone mineral density changes among people living with HIV who have started with TDF-containing regimen: a five-year prospective study. <i>PLoS One</i>. 2020;15(3):e0230368. doi:10.1371/journal.pone.0230368<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tenofovir-disoproxil-fumarate-and-emtricitabine-pediatric-drug-information/abstract-text/32210458/pubmed" id="32210458" target="_blank">32210458</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31179503">
<a name="31179503"></a>Havens PL, Perumean-Chaney SE, Patki A, et al. Changes in bone mass after discontinuation of preexposure prophylaxis with tenofovir disoproxil fumarate/emtricitabine in young men who have sex with men: extension phase results of adolescent trials network protocols 110 and 113. <i>Clin Infect Dis</i>. 2020;70(4):687-691. doi:10.1093/cid/ciz486<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tenofovir-disoproxil-fumarate-and-emtricitabine-pediatric-drug-information/abstract-text/31179503/pubmed" id="31179503" target="_blank">31179503</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16291735">
<a name="16291735"></a>Hazra R, Gafni RI, Maldarelli F, et al. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy for pediatric HIV infection. <i>Pediatrics</i>. 2005;116(6):e846-e854.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tenofovir-disoproxil-fumarate-and-emtricitabine-pediatric-drug-information/abstract-text/16291735/pubmed" id="16291735" target="_blank">16291735</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20811330">
<a name="20811330"></a>Herlitz LC, Mohan S, Stokes MB, Radhakrishnan J, D'Agati VD, Markowitz GS. Tenofovir nephrotoxicity: acute tubular necrosis with distinctive clinical, pathological, and mitochondrial abnormalities. <i>Kidney Int</i>. 2010;78(11):1171-1177. doi:10.1038/ki.2010.318<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tenofovir-disoproxil-fumarate-and-emtricitabine-pediatric-drug-information/abstract-text/20811330/pubmed" id="20811330" target="_blank">20811330</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33247876">
<a name="33247876"></a>Hsu R, Brunet L, Fusco J, et al. Risk of chronic kidney disease in people living with HIV by tenofovir disoproxil fumarate (TDF) use and baseline D:A:D chronic kidney disease risk score. <i>HIV Med</i>. 2021;22(5):325-333. doi:10.1111/hiv.13019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tenofovir-disoproxil-fumarate-and-emtricitabine-pediatric-drug-information/abstract-text/33247876/pubmed" id="33247876" target="_blank">33247876</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17083032">
<a name="17083032"></a>Izzedine H, Hulot JS, Villard E, et al. Association between ABCC2 gene haplotypes and tenofovir-induced proximal tubulopathy. <i>J Infect Dis</i>. 2006;194(11):1481-1491. doi:10.1086/508546<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tenofovir-disoproxil-fumarate-and-emtricitabine-pediatric-drug-information/abstract-text/17083032/pubmed" id="17083032" target="_blank">17083032</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24585896">
<a name="24585896"></a>Jose S, Hamzah L, Campbell LJ, et al. Incomplete reversibility of estimated glomerular filtration rate decline following tenofovir disoproxil fumarate exposure. <i>J Infect Dis</i>. 2014;210(3):363-373. doi:10.1093/infdis/jiu107<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tenofovir-disoproxil-fumarate-and-emtricitabine-pediatric-drug-information/abstract-text/24585896/pubmed" id="24585896" target="_blank">24585896</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22824630">
<a name="22824630"></a>Kalayjian RC, Lau B, Mechekano RN, et al. Risk factors for chronic kidney disease in a large cohort of HIV-1 infected individuals initiating antiretroviral therapy in routine care. <i>AIDS</i>. 2012;26(15):1907-1915. doi:10.1097/QAD.0b013e328357f5ed<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tenofovir-disoproxil-fumarate-and-emtricitabine-pediatric-drug-information/abstract-text/22824630/pubmed" id="22824630" target="_blank">22824630</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23917901">
<a name="23917901"></a>Kuhar DT, Henderson DK, Struble KA, et al. Updated US Public Health Service Guidelines for the Management of Occupational Exposures to Human Immunodeficiency Virus and Recommendations for Postexposure Prophylaxis. <i>Infect Control Hosp Epidemiol.</i> 2013;34(9):875-892.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tenofovir-disoproxil-fumarate-and-emtricitabine-pediatric-drug-information/abstract-text/23917901/pubmed" id="23917901" target="_blank">23917901</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34608820">
<a name="34608820"></a>Linn BS, Vandiver JW, Ren D, Shassetz J. Fanconi syndrome induced by concomitant HIV PrEP and tacrolimus. <i>J Investig Med High Impact Case Rep</i>. 2021;9:23247096211050207. doi:10.1177/23247096211050207<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tenofovir-disoproxil-fumarate-and-emtricitabine-pediatric-drug-information/abstract-text/34608820/pubmed" id="34608820" target="_blank">34608820</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25234519">
<a name="25234519"></a>Lucas GM, Ross MJ, Stock PG, et al. Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2014;59(9): e96-e138.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tenofovir-disoproxil-fumarate-and-emtricitabine-pediatric-drug-information/abstract-text/25234519/pubmed" id="25234519" target="_blank">25234519</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21606537">
<a name="21606537"></a>McComsey GA, Kitch D, Daar ES, et al. Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202. <i>J Infect Dis</i>. 2011;203(12):1791-1801. doi:10.1093/infdis/jir188<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tenofovir-disoproxil-fumarate-and-emtricitabine-pediatric-drug-information/abstract-text/21606537/pubmed" id="21606537" target="_blank">21606537</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28764611">
<a name="28764611"></a>Medland NA, Chow EP, Walker RG, Chen M, Read TR, Fairley CK. Incidence of renal Fanconi syndrome in patients taking antiretroviral therapy including tenofovir disoproxil fumarate. <i>Int J STD AIDS</i>. 2018;29(3):227-236. doi:10.1177/0956462417722133<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tenofovir-disoproxil-fumarate-and-emtricitabine-pediatric-drug-information/abstract-text/28764611/pubmed" id="28764611" target="_blank">28764611</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Microbicide Trials Network (MTN). MTN Statement on Decision to Discontinue Use of Oral Tenofovir Tablets in VOICE, a Major HIV Prevention Study in Women. <i>Microbicide Trials Network.</i> 2011. http://www.mtnstopshiv.org/node/3619.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29136775">
<a name="29136775"></a>Mingione A, Maruca K, Chiappori F, et al. High parathyroid hormone concentration in tenofovir-treated patients are due to inhibition of calcium-sensing receptor activity. <i>Biomed Pharmacother</i>. 2018;97:969-974. doi:10.1016/j.biopha.2017.11.037<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tenofovir-disoproxil-fumarate-and-emtricitabine-pediatric-drug-information/abstract-text/29136775/pubmed" id="29136775" target="_blank">29136775</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26866954">
<a name="26866954"></a>Mirembe BG, Kelly CW, Mgodi N, et al. Bone mineral density changes among young, healthy African women receiving oral tenofovir for HIV preexposure prophylaxis. <i>J Acquir Immune Defic Syndr</i>. 2016;71(3):287-294. doi:10.1097/QAI.0000000000000858<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tenofovir-disoproxil-fumarate-and-emtricitabine-pediatric-drug-information/abstract-text/26866954/pubmed" id="26866954" target="_blank">26866954</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20523203">
<a name="20523203"></a>Mocroft A, Kirk O, Reiss P, et al. Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. <i>AIDS</i>. 2010;24(11):1667-1678. doi:10.1097/QAD.0b013e328339fe53<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tenofovir-disoproxil-fumarate-and-emtricitabine-pediatric-drug-information/abstract-text/20523203/pubmed" id="20523203" target="_blank">20523203</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26624850">
<a name="26624850"></a>Molina JM, Capitant C, Spire B, et al; ANRS IPERGAY Study Group. On-demand preexposure prophylaxis in men at high risk for HIV-1 infection. <i>N Engl J Med.</i> 2015;373(23):2237-2246. doi:10.1056/NEJMoa1506273<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tenofovir-disoproxil-fumarate-and-emtricitabine-pediatric-drug-information/abstract-text/26624850/pubmed" id="26624850" target="_blank">26624850</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25531343">
<a name="25531343"></a>Mugwanya KK, Wyatt C, Celum C, et al. Changes in glomerular kidney function among HIV-1-uninfected men and women receiving emtricitabine-tenofovir disoproxil fumarate preexposure prophylaxis: a randomized clinical trial. <i>JAMA Intern Med</i>. 2015;175(2):246-254. doi:10.1001/jamainternmed.2014.6786<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tenofovir-disoproxil-fumarate-and-emtricitabine-pediatric-drug-information/abstract-text/25531343/pubmed" id="25531343" target="_blank">25531343</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26914909">
<a name="26914909"></a>Mugwanya KK, Wyatt C, Celum C, et al. Reversibility of glomerular renal function decline in HIV-uninfected men and women discontinuing emtricitabine-tenofovir disoproxil fumarate pre-exposure prophylaxis. <i>J Acquir Immune Defic Syndr</i>. 2016;71(4):374-380. doi:10.1097/QAI.0000000000000868<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tenofovir-disoproxil-fumarate-and-emtricitabine-pediatric-drug-information/abstract-text/26914909/pubmed" id="26914909" target="_blank">26914909</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34856908">
<a name="34856908"></a>Ozcan SN, Sevgi DY, Oncul A, et al. The prevalence and associated factors of reduced bone mineral density (BMD) among men with suppressed viral load taking antiretroviral therapy. <i>Curr HIV Res</i>. 2022;20(1):74-81. doi:10.2174/1570162X19666211202100308<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tenofovir-disoproxil-fumarate-and-emtricitabine-pediatric-drug-information/abstract-text/34856908/pubmed" id="34856908" target="_blank">34856908</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21808434">
<a name="21808434"></a>Patel KK, Patel AK, Ranjan RR, Patel AR, Patel JK. Tenofovir-associated renal dysfunction in clinical practice: an observational cohort from western India. <i>Indian J Sex Transm Dis AIDS</i>. 2010;31(1):30-34. doi:10.4103/0253-7184.68998<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tenofovir-disoproxil-fumarate-and-emtricitabine-pediatric-drug-information/abstract-text/21808434/pubmed" id="21808434" target="_blank">21808434</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21076445">
<a name="21076445"></a>Perazella MA. Tenofovir-induced kidney disease: an acquired renal tubular mitochondriopathy. <i>Kidney Int</i>. 2010;78(11):1060-1063. doi:10.1038/ki.2010.344<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tenofovir-disoproxil-fumarate-and-emtricitabine-pediatric-drug-information/abstract-text/21076445/pubmed" id="21076445" target="_blank">21076445</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18346519">
<a name="18346519"></a>Purdy JB, Gafni RI, Reynolds JC, Zeichner S, Hazra R. Decreased bone mineral density with off-label use of tenofovir in children and adolescents infected with human immunodeficiency virus. <i>J Pediatr</i>. 2008;152(4):582-584.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tenofovir-disoproxil-fumarate-and-emtricitabine-pediatric-drug-information/abstract-text/18346519/pubmed" id="18346519" target="_blank">18346519</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31269294">
<a name="31269294"></a>Ramalho J, Martins CSW, Galvão J, et al. Treatment of human immunodeficiency virus infection with tenofovir disoproxil fumarate-containing antiretrovirals maintains low bone formation rate, but increases osteoid volume on bone histomorphometry. <i>J Bone Miner Res</i>. 2019;34(9):1574-1584. doi:10.1002/jbmr.3751<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tenofovir-disoproxil-fumarate-and-emtricitabine-pediatric-drug-information/abstract-text/31269294/pubmed" id="31269294" target="_blank">31269294</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34073672">
<a name="34073672"></a>Rao M, Dadey L, Glowa T, Veldkamp P. Fanconi syndrome leading to hypophosphatemic osteomalacia related to tenofovir use. <i>Infect Dis Rep</i>. 2021;13(2):448-453. doi:10.3390/idr13020044<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tenofovir-disoproxil-fumarate-and-emtricitabine-pediatric-drug-information/abstract-text/34073672/pubmed" id="34073672" target="_blank">34073672</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26401025">
<a name="26401025"></a>Rokx C, Alshangi H, Verbon A, Zietse R, Hoorn EJ, Rijnders BJ. Renal toxicity of concomitant exposure to tenofovir and inhibitors of tenofovir's renal efflux transporters in patients infected with HIV type 1. <i>J Infect Dis</i>. 2016;213(4):561-568. doi:10.1093/infdis/jiv466<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tenofovir-disoproxil-fumarate-and-emtricitabine-pediatric-drug-information/abstract-text/26401025/pubmed" id="26401025" target="_blank">26401025</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34139202">
<a name="34139202"></a>Rukuni R, Rehman AM, Mukwasi-Kahari C, et al. Effect of HIV infection on growth and bone density in peripubertal children in the era of antiretroviral therapy: a cross-sectional study in Zimbabwe. <i>Lancet Child Adolesc Health</i>. 2021;5(8):569-581. doi:10.1016/S2352-4642(21)00133-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tenofovir-disoproxil-fumarate-and-emtricitabine-pediatric-drug-information/abstract-text/34139202/pubmed" id="34139202" target="_blank">34139202</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33052386">
<a name="33052386"></a>Saag MS, Gandhi RT, Hoy JF, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2020 recommendations of the International Antiviral Society-USA Panel. <i>JAMA</i>. 2020;324(16):1651-1669. doi:10.1001/jama.2020.17025<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tenofovir-disoproxil-fumarate-and-emtricitabine-pediatric-drug-information/abstract-text/33052386/pubmed" id="33052386" target="_blank">33052386</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35132821">
<a name="35132821"></a>Sahoo RR, Wakhlu A. Clinical images: tenofovir-induced Fanconi syndrome: an uncommon cause of hypophosphatemic osteomalacia. <i>ACR Open Rheumatol</i>. 2022;10.1002/acr2.11415. doi:10.1002/acr2.11415<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tenofovir-disoproxil-fumarate-and-emtricitabine-pediatric-drug-information/abstract-text/35132821/pubmed" id="35132821" target="_blank">35132821</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22313955">
<a name="22313955"></a>Scherzer R, Estrella M, Li Y, et al. Association of tenofovir exposure with kidney disease risk in HIV infection. <i>AIDS</i>. 2012;26(7):867-875. doi:10.1097/QAD.0b013e328351f68f<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tenofovir-disoproxil-fumarate-and-emtricitabine-pediatric-drug-information/abstract-text/22313955/pubmed" id="22313955" target="_blank">22313955</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23896476">
<a name="23896476"></a>Stray KM, Bam RA, Birkus G, et al. Evaluation of the effect of cobicistat on the in vitro renal transport and cytotoxicity potential of tenofovir. <i>Antimicrob Agents Chemother</i>. 2013;57(10):4982-4989. doi:10.1128/AAC.00712-13<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tenofovir-disoproxil-fumarate-and-emtricitabine-pediatric-drug-information/abstract-text/23896476/pubmed" id="23896476" target="_blank">23896476</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35143730">
<a name="35143730"></a>Suppadungsuk S, Janepiriyaprayoon P, Sungkanuparph S. Recovery of renal function after early versus late switching of tenofovir disoproxil fumarate in people living with HIV with renal insufficiency. <i>Int J STD AIDS</i>. 2022;33(4):391-396. doi:10.1177/09564624221076632<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tenofovir-disoproxil-fumarate-and-emtricitabine-pediatric-drug-information/abstract-text/35143730/pubmed" id="35143730" target="_blank">35143730</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22784038">
<a name="22784038"></a>Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral Preexposure Prophylaxis for Heterosexual HIV Transmission in Botswana. <i>N Engl J Med.</i> 2012;367(5):423-434.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tenofovir-disoproxil-fumarate-and-emtricitabine-pediatric-drug-information/abstract-text/22784038/pubmed" id="22784038" target="_blank">22784038</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Truvada (emtricitabine/tenofovir disoproxil fumarate) [prescribing information]. Foster City, CA: Gilead Sciences; October 2023.</div>
</li>
<li>
<div class="reference">
                  Truvada (emtricitabine/tenofovir) [product monograph]. Mississauga, Ontario, Canada: Gilead Sciences Canada Inc; July 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.4">
<a name="HHS.4"></a>US Department of Health and Human Services (HHS). Updated Guidelines for Antiretroviral Postexposure Prophylaxis After Sexual, Injection Drug Use, or Other Nonoccupational Exposure to HIV - United States, 2016. <a href="https://stacks.cdc.gov/view/cdc/38856" target="_blank">https://stacks.cdc.gov/view/cdc/38856</a>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.1">
<a name="HHS.1"></a>US Department of Health and Human Services (HHS) Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. HIV.gov. Updated January 20, 2022. Accessed May 9, 2022. <a href="https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-arv/whats-new-guidelines" target="_blank">https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-arv/whats-new-guidelines</a>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.5">
<a name="HHS.5"></a>US Department of Health and Human Services (HHS) Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. <a href="https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-arv/whats-new-guidelines" target="_blank">https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-arv/whats-new-guidelines</a>. Updated December 18, 2019. Accessed December 18, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.2">
<a name="HHS.2"></a>US Department of Health and Human Services (HHS) Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV. Guidelines for the use of antiretroviral agents in pediatric HIV infection. HIV.gov. Updated April 11, 2022. Accessed May 9, 2022. <a href="https://clinicalinfo.hiv.gov/en/guidelines/pediatric-arv/whats-new-guidelines" target="_blank">https://clinicalinfo.hiv.gov/en/guidelines/pediatric-arv/whats-new-guidelines</a>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.3">
<a name="HHS.3"></a>US Department of Health and Human Services (HHS) Panel on Treatment of HIV During Pregnancy and Prevention of Perinatal Transmission. Recommendations for the use of antiretroviral drugs during pregnancy and interventions to reduce perinatal HIV transmission in the United States. <a href="https://clinicalinfo.hiv.gov/en/guidelines/perinatal/whats-new" target="_blank">https://clinicalinfo.hiv.gov/en/guidelines/perinatal/whats-new</a>. Updated January 31, 2023. Accessed February 23, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22784040">
<a name="22784040"></a>Van Damme L, Corneli A, Ahmed K, et al. Preexposure prophylaxis for HIV infection among African women. <i>N Engl J Med.</i> 2012;367(5):411-422.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tenofovir-disoproxil-fumarate-and-emtricitabine-pediatric-drug-information/abstract-text/22784040/pubmed" id="22784040" target="_blank">22784040</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20173649">
<a name="20173649"></a>Wever K, van Agtmael MA, Carr A. Incomplete reversibility of tenofovir-related renal toxicity in HIV-infected men. <i>J Acquir Immune Defic Syndr</i>. 2010;55(1):78-81. doi:10.1097/QAI.0b013e3181d05579<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tenofovir-disoproxil-fumarate-and-emtricitabine-pediatric-drug-information/abstract-text/20173649/pubmed" id="20173649" target="_blank">20173649</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23739150">
<a name="23739150"></a>Wikman P, Safont P, Del Palacio M, Moreno A, Moreno S, Casado JL. The significance of antiretroviral-associated acute kidney injury in a cohort of ambulatory human immunodeficiency virus-infected patients. <i>Nephrol Dial Transplant</i>. 2013;28(8):2073-2081. doi:10.1093/ndt/gft210<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tenofovir-disoproxil-fumarate-and-emtricitabine-pediatric-drug-information/abstract-text/23739150/pubmed" id="23739150" target="_blank">23739150</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23430209">
<a name="23430209"></a>Zaidan M, Lescure FX, Brochériou I, et al. Tubulointerstitial nephropathies in HIV-infected patients over the past 15 years: a clinico-pathological study. <i>Clin J Am Soc Nephrol</i>. 2013;8(6):930-938. doi:10.2215/CJN.10051012<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tenofovir-disoproxil-fumarate-and-emtricitabine-pediatric-drug-information/abstract-text/23430209/pubmed" id="23430209" target="_blank">23430209</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16355343">
<a name="16355343"></a>Zimmermann AE, Pizzoferrato T, Bedford J, Morris A, Hoffman R, Braden G. Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions. <i>Clin Infect Dis</i>. 2006;42(2):283-290. doi:10.1086/499048<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tenofovir-disoproxil-fumarate-and-emtricitabine-pediatric-drug-information/abstract-text/16355343/pubmed" id="16355343" target="_blank">16355343</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 13013 Version 422.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
